Synthetic Biologics (SYN) said Wednesday that Frank Tufaro has been named chief operating officer. Tufaro was COO of VCN Biosciences, which was acquired by...
Synthetic Biologics (SYN) said Friday it has closed on its acquisition of clinical-stage biotech company VCN Biosciences. Synthetic said it paid $4.7...
Synthetic Biologics (SYN) said Tuesday that the US Food and Drug Administration has granted orphan drug designation to VCN Biosciences' VCN-01 for the...
Synthetic Biologics (SYN) said Tuesday it has signed a definitive agreement to acquire VCN Biosciences, which is currently developing a potential treatment...
| Address | 9605 Medical Center Drive Rockville, Maryland 20850 |
| Phone | +1.301.417.4364 |
| Number of Employees | 13 |
| Recent SEC Filing | 05/16/2022 10-Q |
| CEO, CFO, Treasurer & Director | Steven A. Shallcross |
| Chief Operating Officer | Frank Tufaro |
| Senior Vice President-Research & Development | Michael Kaleko |
| Director General-European Region | Manel Cascalló |
| Price Open | $0.20 |
| Previous Close | $0.20 |
| 52 Week Range | $0.18 - 0.64 |
| Market Capitalization | $31.7 M |
| Shares Outstanding | 158.4 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/04/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.12 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -22.60% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
